Targets › POLB
5 programs from 3 companies in 11 trials: 6 Phase 3, 3 Phase 2, 1 Phase 1, 1 Phase 4; Infectious disease, Oncology, Neurology; next expected readout Nov 2026.
Repair polymerase that plays a key role in base-excision repair. During this process, the damaged base is excised by specific DNA glycosylases, the DNA backbone is nicked at the abasic site by an apurinic/apyrimidic (AP) endonuclease, and POLB removes 5'-deoxyribose-phosphate from the preincised AP site acting as a 5'-deoxyribose-phosphate lyase (5'-dRP lyase); through its DNA polymerase activity, it adds one…. (UniProt, P06746)
Open in Phaseline: the race on POLB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| José Antonio Mata Marín | Darunavir Human immunodeficiency virus type 1 protease inhibitor | CYP3A4, POLB | Phase 4 | HIV Infection | Nov 2026 |
| Sun Yat-sen University | Entecavir DNA polymerase/reverse transcriptase inhibitor | POLG, POLB | Phase 3 | Gastrointestinal Cancers; Resolved Hepatitis B | Dec 2026 |
| Gilead Sciences | Tenofovir Disoproxil Fumarate Human immunodeficiency virus type 1 reverse transcriptase inhibitor | POLA1, POLB | Phase 3 | Chronic Hepatitis B; Hepatitis B; Hepatitis B Infection; Parkinson Disease | Jul 2027 |
| Gilead Sciences | Islatravir Reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor | RT, IN, POLB, INTS1, INTS8 | Phase 3 | HIV-1-Infection; HIV-1-infection; HIV-1 Infection | Mar 2028 |
| Gilead Sciences | ISL/LEN FDC Fixed-dose combination of nucleotide reverse transcriptase translocation inhibitor and HIV | POLB, GAG | Phase 2 | HIV-1 Infection | Mar 2028 |
HIV-1 Infection (2) Gastrointestinal Cancers (1) Resolved Hepatitis B (1) HIV-1-Infection (1) HIV-1-infection (1) Chronic Hepatitis B (1) Hepatitis B (1) Hepatitis B Infection (1) Parkinson Disease (1) HIV Infection (1)
small molecule (5)
Gilead Sciences (3) Sun Yat-sen University (1) José Antonio Mata Marín (1)
POLG (1) RT (1) IN (1) INTS1 (1) INTS8 (1) POLA1 (1) GAG (1) CYP3A4 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.